Blood and Bone Marrow Cancer Treatment Market By Indication (Multiple Myeloma, Leukemia, Lymphoma and Others), By Therapy (Chemotherapy, Immunotherapy, Stem Cell Transplant and Radiotherapy) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Blood and Bone Marrow Cancer Treatment Market
2.2. Global Blood and Bone Marrow Cancer Treatment Market, By Indication, 2023 (US$ Million)
2.3. Global Blood and Bone Marrow Cancer Treatment Market, By Therapy, 2023 (US$ Million)
2.4. Global Blood and Bone Marrow Cancer Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023
3. Blood and Bone Marrow Cancer Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Blood and Bone Marrow Cancer Treatment Market Vendors
3.2. Strategies Adopted by Blood and Bone Marrow Cancer Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032
4. Blood and Bone Marrow Cancer Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Blood and Bone Marrow Cancer Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape
5. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Multiple Myeloma
5.3.2. Leukemia
5.3.3. Lymphoma
5.3.4. Others
6. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Stem Cell Transplant
6.3.4. Radiotherapy
6.3.5. Pipeline Analysis
6.3.5.1. Phase III Drug
6.3.5.1.1. Eltrombopag
6.3.5.1.2. Avatrombopag
6.3.5.1.3. Hetrombopag
6.3.5.1.4. Omidubicel
6.3.5.1.5. Fedratinib
6.3.5.1.6. ATIR101
6.3.5.1.7. Pegylated Proline Interferon Alpha-2b
6.3.5.2. Tabular Representation of Phase II and I Pipeline Drugs
7. North America Blood and Bone Marrow Cancer Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
7.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
7.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
7.4.1.1.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
7.4.1.2.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
7.4.1.3.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8. UK and European Union Blood and Bone Marrow Cancer Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.1.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.2.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.3.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.4.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.5.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
8.4.1.6.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9. Asia Pacific Blood and Bone Marrow Cancer Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.1.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.2.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.3.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.4.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.5.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
9.4.1.6.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
10. Latin America Blood and Bone Marrow Cancer Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
10.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
10.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
10.4.1.1.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
10.4.1.2.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
10.4.1.3.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
11. Middle East and Africa Blood and Bone Marrow Cancer Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
11.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
11.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
11.4.1.1.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
11.4.1.2.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2022-2032, USD (Million)
11.4.1.3.2. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2022-2032, USD (Million)
12. Company Profile
12.1. AstraZeneca, Plc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Celgene, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bristol Myers Squibb & Company
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Eli Lilly & Company
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Johnson & Johnson Company
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. F.Hoffman La-Roche Ltd.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Pfizer, Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Varian Medical Systems, Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives